Connor, Clark & Lunn Investment Management Ltd. Enanta Pharmaceuticals Inc Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 24,636 shares of ENTA stock, worth $209,159. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,636
Previous 11,768
109.35%
Holding current value
$209,159
Previous $122,000
15.57%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ENTA
# of Institutions
108Shares Held
19.7MCall Options Held
9.7KPut Options Held
12.4K-
Krensavage Asset Management, LLC New York, NY2.12MShares$18 Million7.2% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.11MShares$17.9 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.98MShares$16.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.85MShares$15.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.22MShares$10.4 Million0.0% of portfolio
About ENANTA PHARMACEUTICALS INC
- Ticker ENTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,724,900
- Market Cap $176M
- Description
- Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...